Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter Heart Valve At The Transcatheter Cardiovascular Therapeutics Conference, October 31-November 3

The presentation will report 30-day outcomes in patients with severe aortic stenosis who received the medium-size DurAVR THV in the ongoing EMBARK study. Since 2021 over 130 patients have been treated with the DurAVR THV across different valve sizes in the Company’s EMBARK study and Early Feasibility Study (EFS).

In a separate session on emerging TAVR technologies, Santiago Garcia, MD, will present "DurAVR TAVR (ANTERIS): Technology and Case-in-a-Box", featuring the biomimetic DurAVR THV, a new class of transcatheter aortic valve replacement (TAVR).

Session details are as follows:

1)   TCT Innovation 3: Emerging Concepts and Innovations in TAVR

Sunday, November 1, 2026, 10:45 AM - 12:15 PM PST

Room: Innovation Theater

The Novel Biomimetic Medium DurAVR THV Balloon-Expandable Valve (Anteris): First Report of the 30-Day Clinical and Hemodynamic Outcomes

Presenter: Azeem Latib, MD

2)   TCT Innovation 15: Live Case-in-a-Box Innovation: Emerging TAVR Technologies

Tuesday, November 3, 2026, 8:35 – 9:35 AM PST

Room: Innovation Theater

DurAVR TAVR (ANTERIS): Technology and Case-in-a-Box

Presenter: Santiago Garcia, MD